Daiken Biomedical CoTPE:7780 +1.66%23 ROA % is 8.62% as of Dec. 2025, which is 35% below its 10-year median of 13.18. GuruFocus rates TPE:7780 with a GF Score™ of 23/100. The stock has 6 warning signs investors should review. Among 1,987 Consumer Packaged Goods companies, Daiken Biomedical Co ranks better than 84% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Daiken Biomedical Co's annualizedNet Income for the quarter that ended in Dec. 2025 was NT$499 Mil.
Daiken Biomedical Co's average Total Assets over the quarter that ended in Dec. 2025 was NT$5,783 Mil. Therefore, Daiken Biomedical Co's annualized ROA % for the quarter that ended in Dec. 2025 was 8.62%.
The historical rank and industry rank for Daiken Biomedical Co's ROA % or its related term are showing as below:
TPE:7780'
s ROA % Range Over the Past 10 Years
Min: 9.07 Med: 13.18 Max: 25.15
Current: 10.27
During the past 4 years, Daiken Biomedical Co's highest ROA % was 25.15%. The lowest was 9.07%. And the median was 13.18%.
TPE:7780's ROA % is ranked better than 84% of 1987
companies
in the Consumer Packaged Goods industry
Industry Median: 3.24
vs TPE:7780: 10.27
Daiken Biomedical Co (TPE:7780) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Daiken Biomedical Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiken Biomedical Co ROA % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Daiken Biomedical Co's ROA % distribution charts can be found below:
* The bar in red indicates where Daiken Biomedical Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Daiken Biomedical Co (TPE:7780) has a ROA % of 8.62% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Daiken Biomedical Co and its competitors. This is 35% below median its historical median of 13.18. Over the past decade, Daiken Biomedical Co's ROA % has ranged from 9.07 to 25.15. According to the industry distribution chart, Daiken Biomedical Co ranks #318 out of 1987 companies in the Consumer Packaged Goods industry, placing it in the top 16%.
Is Daiken Biomedical Co's ROA % too high?
Daiken Biomedical Co's current ROA % of 8.62% is 35% below median its 10-year median of 13.18. Over the past 10 years, this metric has ranged from a low of 9.07 to a high of 25.15. The Consumer Packaged Goods industry median ROA % is 3.24. Daiken Biomedical Co's value of 8.62% is 166% above this industry median. Based on the distribution chart, Daiken Biomedical Co ranks #318 out of 1987 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Daiken Biomedical Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Daiken Biomedical Co's ROA % compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Daiken Biomedical Co ranks #318 out of 1987 companies for ROA %. This places Daiken Biomedical Co in the top 16% of its industry — outperforming the majority of peers. The industry median ROA % is 3.24. Daiken Biomedical Co's value of 8.62% is 166% above this benchmark. Historically, Daiken Biomedical Co's own ROA % has ranged from 9.07 to 25.15 over the past decade. While the company's 10-year median is 13.18 vs. the industry median of 3.24, Daiken Biomedical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Consumer Packaged Goods company?
The median ROA % among Consumer Packaged Goods companies is 3.24, based on 1,987 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daiken Biomedical Co's current ROA % of 8.62% is 166% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Daiken Biomedical Co and its competitors. For the Consumer Packaged Goods industry, the median ROA % is 3.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daiken Biomedical Co's current ROA % is 8.62%, which is 35% below median its own 10-year median of 13.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiken Biomedical Co stock overvalued right now?
Daiken Biomedical Co (TPE:7780) has a current ROA % of 8.62%. The current ROA % is 8.62%, which is 35% below median its 10-year median of 13.18 and 166% above the Consumer Packaged Goods industry median of 3.24. Daiken Biomedical Co's overall GF Score™ is 23/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Daiken Biomedical Co (TPE:7780), the current ROA % is 8.62% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Daiken Biomedical Co Ltd is engaged in Research, development, and sales of health food. Its products include fish oil capsules, collagen powder, collagen drinks, natto capsules, and mint leaf capsules. The companies reportable operating segment consists solely of the e-commerce division.
23GF Score
Get the complete analysis for TPE:7780
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:7780 has been successfully added to your 
